A designed Tat immunogen generates enhanced anti-Tat C-terminal antibodies
2012; Elsevier BV; Volume: 30; Issue: 14 Linguagem: Inglês
10.1016/j.vaccine.2012.01.055
ISSN1873-2518
AutoresWenting Liao, Qiuli Chen, Jie Cao, Guangguo Tan, Zhenyu Zhu, Huaqun Zhang, Yifeng Chai, Wei Pan,
Tópico(s)Monoclonal and Polyclonal Antibodies Research
ResumoHIV-1 Tat has been identified as an attractive target for vaccine development and is currently under investigation in clinical trials as both a therapeutic and preventative vaccine for HIV-1. The Tat C-terminal region is of significant importance for its extracellular activity. In this study, we designed two recombinant Tat immunogens, Tat(B41-100N) and Tat(B41-100C), with two extended Tat C-terminal regions (41–100 aa) and compared their humoral immune response with native Tat. Interestingly, our results showed that Tat(B41-100C) elicited a higher antibody titer than Tat and Tat(B41-100N) in both mice and rabbits. The recombinant fusion protein-based epitope analysis showed that Tat(B41-100C) induced a remarkably enhanced humoral immune response against extended Tat C-terminal regions containing residues 38–100, 49–100 and 60–100. Our study demonstrates that the designed Tat(B41-100C) presents a designed immunogenicity that elicits enhanced Tat-specific antibodies especially against extended Tat C-terminal regions.
Referência(s)